Generic Name and Formulations:
Methylphenidate HCl 20mg; ext-rel tabs; dye-free; contains sucrose.
Adults and Children:
Swallow whole. <6yrs: not established. ≥6yrs: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily.
Indications for METADATE ER:
Adults and Children:
Swallow whole. <6yrs: not recommended. ≥6yrs: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily.
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Severe hypertension. Angina. Cardiac arrhythmias. Heart failure. Recent MI. Hyperthyroidism. Thyrotoxicosis. Glaucoma. Surgery. History of tics or Tourette's syndrome in patient or family.
History of drug dependence or alcoholism; monitor. Structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems: not recommended. Pre-existing hypertension. Assess cardiovascular status. Psychosis. Bipolar disorder. Mania. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. Risk of peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor growth, HR, BP, CBC, differential, and platelet counts. Interrupt therapy if growth suppression occurs. Reduce dose or discontinue if paradoxical worsening of symptoms occur. Re-evaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Avoid alcohol. Caution with pressor agents. May potentiate anticonvulsants (eg, phenobarbital, phenytoin, primidone), oral anticoagulants, tricyclics, SSRIs, phenylbutazone. May be affected by agents that alter urinary pH.
Headache, anorexia, abdominal pain, dizziness, rash, insomnia, nervousness, blood dyscrasias, weight loss, nausea, dyskinesias, tachycardia, arrhythmias; priapism, Tourette's syndrome, toxic psychosis, seizures, hypertension, visual disturbances.
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D